ArticleToxicology reports2025
Immune-related adverse events in immunotherapy: Challenges in diagnosis, monitoring, and management.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Checkpoint inhibitor-induced hematologic immune-related adverse events and their association with disease recurrence in hematolymphoid malignancies: a clinical perspective.Blood research · 2026Review
- Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1.Discover oncology · 2026Review
- Targeting tumor-infiltrating regulatory T cells based on immunometabolism.Cancer biology & medicine · 2026Review
- Editorial: Special issue on Current developments in immunotherapy and related toxicities.Toxicology reports · 2025Article
- Immune checkpoint inhibitor-related arthritis and oral disorders: shared pathophysiology and clinical implications for rheumatology and oral health.Cancer cell international · 2025Review
- CTLA-4 and targeted immunotherapy-a key link in the systemic influence of periodontitis: a mini review.Frontiers in dental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article provides a comprehensive overview of safety and monitoring guidelines in immunotherapy, a rapidly advancing field in cancer and autoimmune treatment. Immunotherapy, which harnesses the body's immune system to combat diseases, has shown remarkable promise but presents unique safety challenges requiring rigorous oversight. The article examines various immunotherapies, including immune checkpoint inhibitors, monoclonal antibodies, and cytokine therapies, highlighting potential adverse effects and the critical need for careful monitoring. It emphasizes pre-treatment assessments, risk stratification, and genetic and biomarker screening to identify high-risk patients. Detailed monitoring protocols, including laboratory tests, imaging, and clinical evaluations, are discussed to detect immune-related adverse events (irAEs) early. Strategies for managing both acute and chronic toxicities, such as dose adjustments and treatment interruptions, are outlined to ensure timely intervention and individualized care. The article also underscores the importance of patient education, compliance, and supportive care, emphasizing a multidisciplinary approach. Through this detailed review, healthcare professionals gain practical guidelines to optimize the safe and effective use of immunotherapies in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.